Back to top
more

Entrada Therapeutics (TRDA)

(Delayed Data from NSDQ)

$16.78 USD

16.78
186,586

+0.97 (6.14%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $16.78 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Anavex (AVXL) Rises as CHMP Deems Blarcamesine Eligible for MAA

The CHMP agrees that Anavex's (AVXL) blarcamesine for Alzheimer's disease is eligible for submission for a Union Marketing Authorisation in the EU. Shares rise.

Invivyd (IVVD) Surges on Positive Data From COVID-19 Study

Invivyd (IVVD) reports positive initial data from the phase III CANOPY study on VYD222 for the prevention of symptomatic COVID-19. Stock shoots up on the news.

Arcutis (ARQT) Up on FDA Nod for Zoryve in Seborrheic Dermatitis

The FDA approves Arcutis' (ARQT) NDA for Zoryve topical foam 0.3% for treating seborrheic dermatitis in individuals nine years of age and above.

Mirum (MIRM) Down on Failure of Mid-Stage Study on Livmarli

Mirum (MIRM) faces a setback in its efforts to expand its lead drug Livmarli's label for the indication of biliary atresia in patients who have undergone a Kasai surgery.

Bristol Myers (BMY) Stops Late-Stage Colorectal Cancer Study

Bristol Myers (BMY) decides to discontinue the phase III colorectal cancer study as it was unlikely to meet its primary endpoints upon completion.

Gilead (GILD) Outperforms Industry in 6 Months: What Lies Ahead?

Gilead (GILD) gains 3.7% in six months as its oncology portfolio gains traction and its HIV business maintains momentum.

NextCure (NXTC) Down on Shelving Plans to Develop Candidate

NextCure (NXTC) plans to focus on developing LNCB74 and stop the development of NC762 to conserve cash. The company's shares decline on the same.

Apellis (APLS) Falls on Europe Update for Pegcetacoplan in GA

The CHMP may adopt a negative opinion on Apellis' (APLS) intravitreal pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration in the EU. Stock declines.

Amgen's (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC

Amgen's (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDA's priority review. A decision is expected on Jun 12, 2024.

C4 Therapeutics (CCCC) Soars on Oncology Deal With Merck

C4 Therapeutics (CCCC) inks an agreement with Merck to discover and develop degrader-antibody conjugates with a focus on one oncology target. Shares rise on the same.

Candel (CADL) Rises on FDA's Fast Track Status for CAN-2409

The FDA gives Fast Track designation to Candel's (CADL) lead candidate, CAN-2409 plus prodrug (valacyclovir), for the treatment of patients with pancreatic cancer.

GSK's Jemperli Gets EU Nod for Endometrial Cancer Expanded Use

GSK's Jemperli combo receives the European Commission's marketing authorization as a frontline treatment for certain types of primary advanced/recurrent endometrial cancer.

Pfizer's (PFE) Multiple Myeloma Drug Elrexfio Gets Nod in EU

Pfizer's (PFE) targeted immunotherapy, Elrexfio, for treating heavily pretreated adults with relapsed/refractory multiple myeloma gets EC's conditional marketing authorization.

Merck's (MRK) Keytruda, Lenvima Endometrial Cancer Study Fails

The combination of Merck's (MRK) Keytruda and Eisai's Lenvima for the first-line treatment of advanced/recurrent endometrial carcinoma fails to meet dual primary endpoints in late-stage study.

bluebird (BLUE) Down Despite FDA Nod to Gene Therapy for SCD

bluebird (BLUE) receives FDA approval for its third gene therapy. However, the label carries a black box warning, on which its shares have slumped.

Will Bristol Myers' (BMY) Efforts to Boost Portfolio be Enough?

Shares of Bristol Myers (BMY) have been impacted by pipeline bottlenecks and its key drugs face generic competition. We take a look at the company's efforts to counter these.

Regeneron (REGN) Posts Positive Data on Blood Cancer Candidate

Regeneron's (REGN) multiple myeloma candidate demonstrates strong rates and depth of response in pre-treated patients.

Kymera (KYMR) Rises as Dosing Begins in AD Study on KT-474

Kymera (KYMR) receives a $15 million milestone payment from Sanofi as dosing begins in a phase II study evaluating KT-474 for treating atopic dermatitis. Shares rise on the same.

Syros (SYRS) Rises on Upbeat Initial Study Data on Tamibarotene

Syros (SYRS) posts encouraging initial data from the phase II SELECT-AML-1 study evaluating tamibarotene in combination with venetoclax and azacitidine to treat acute myeloid leukemia.

Travere (TVTX) Up on Latest Portfolio Updates & Reorganization

Travere (TVTX) to submit an sNDA to the FDA to convert the accelerated approval for Filspari to full approval for IgAN in first-quarter 2024. The company is implementing a strategic reorganization to cut costs. Stock rises.

Novartis (NVS) Gets FDA Nod for Rare Blood Disorder Drug

Novartis (NVS) obtains FDA approval for Fabhalta, the first oral monotherapy for treating adults with PNH.

Roche (RHHBY) Breast Cancer Drug Meets Primary Goal in Phase III

Roche's (RHHBY) phase III study evaluating inavolisib in combination with advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation achieves its primary goal.

Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug

The FDA accepts Vanda's (VNDA) new drug application ("NDA") for tradipitant for treating the symptoms of gastroparesis. The company's shares rise in after-hours trading.

AstraZeneca (AZN) to Discontinue Two Studies on Lokelma

Owing to increased enrollment timelines and low event rates, AstraZeneca (AZN) plans to stop the STABILIZE-CKD and DIALIZE-Outcomes phase III evidence studies for the hyperkalemia drug Lokelma.

bluebird bio (BLUE) Stock Gains 25.6% in a Month: Here's How

bluebird bio (BLUE) rises 25.6% in past thirty days on upbeat earnings results and promising progress with its approved therapies.